1429-66-9Relevant articles and documents
Synthesis of reversed structured triacylglycerols possessing EPA and DHA at their terminal positions
Gudmundsdottir, Anna V.,Hansen, Kaj-Anders,Magnusson, Carlos D.,Haraldsson, Gudmundur G.
, p. 8544 - 8550 (2015)
This report describes synthesis of reversed structured triacylglycerols (TAGs) of the LML type, possessing pure EPA or DHA located at the terminal 1,3-positions of the glycerol backbone along with pure even number saturated fatty acids (C6:0–C16:0) occupying the 2-position. These compounds were synthesized by a two-step chemoenzymatic route involving a highly regioselective immobilized Candida antarctica lipase to incorporate EPA or DHA activated as acetoxime esters exclusively into the 1,3-positions of glycerol. The saturated fatty acyl groups were subsequently introduced to the remaining 2-position by EDCI coupling agent to accomplish the title compounds highly efficiently. This is the first report on reversed structured TAGs possessing the long-chain n-3 polyunsaturated fatty acids. It is anticipated that these novel compounds and their synthetic methodology will find various important uses such as analytical standards, in screening for bioactivity and in the pharmaceutical area as prodrugs.
Chemoenzymatic synthesis of structured triacylglycerols by highly regioselective acylation
Halldorsson, Arnar,Magnusson, Carlos D.,Haraldsson, Gudmundur G.
, p. 9101 - 9109 (2003)
A highly efficient two-step chemoenzymatic synthesis of structured triacylglycerols comprising a pure n-3 polyunsaturated fatty acid at the mid-position and a pure saturated fatty acid located at the end-positions is described. In the first step an immobilized Candida antarctica lipase was observed to display an excellent regioselectivity toward the end-positions of glycerol at 0-4°C using vinyl esters as acylating agents. The n-3 fatty acids were introduced into the remaining mid-position highly efficient and in excellent yields using EDCI coupling agent.
A new sunscreen of the cinnamate class: Synthesis and enzymatic hydrolysis evaluation of glyceryl esters of p-methoxycinnamic acid
De Freitas, Zaida Maria Faria,Dos Santos, Elisabete Pereira,Da Rocha, Joao Ferreira,Dellamora-Ortiz, Gisela Maria,Goncalves, Jose Carlos Saraiva
, p. 67 - 72 (2005)
Glyceryl esters of p-methoxycinnamic acid, 1,3-dipalmitoyl-2-p- methoxycinnamoyl-1,2,3-propanetriol and 1,3-dioctanoyl-2-p-methoxycinnamoyl-1,2, 3-propanetriol were synthesised in an attempt to increase substantivity and decrease eventual undesirable effects of sunscreens of this class. To assess if the glyceryl esters could present a higher stability towards hydrolysis by lipases in the stratum corneum, hydrolysis rates were determined in vitro using a commercial fungal lipase from Rhizomucor miehei. Results presented herein show that the glyceryl esters have similar λmax and ε values to sunscreens of the cinnamate class. The ester 1,3-dipalmitoyl-2-p- methoxycinnamoyl-1,2,3-propanetriol presented a 2.8 times lower hydrolysis rate by lipase, in vitro, than the commercial sunscreen 2-ethylhexyl-p- methoxycinnamate (alkyl ester). This finding suggests that this triacylglycerol can possibly have a longer retention time in the skin and consequently promote a more intense and effective antisolar action than the commercial sunscreen.
METHOD FOR PREPARING MONOGLYCERIDES
-
Paragraph 0079-0081; 0084; 0085, (2020/08/18)
The present application relates to a method for preparing monoglycerides, a method for recovering glycerin and catalysts after the process for preparing monoglycerides, and a process for preparing cyclic monoglycerides.(AA) Fatty acid glycerin catalyst(BB) Esterification(CC) Reuse(DD) Settling and separation(EE) Glycerin and most of catalyst(F1,F2) Glyceride layer(GG) Glycerin(HH) Washing and separation(II) Glycerin and traces of catalyst(JJ) Glyceride layer(KK) Molecular distillation(LL) Glycerin and unreacted fatty acid(MM) Di- and tri-glycerideCOPYRIGHT KIPO 2020
LIPID PRODRUGS OF BTK INHIBITORS AND USES THEREOF
-
, (2020/09/12)
The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, and methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.
